Trials / Active Not Recruiting
Active Not RecruitingNCT05488366
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
A Pilot Study of Immunotherapy Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma. These are subjects who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curative surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Given IV |
| RADIATION | Radiation therapy | Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection. |
Timeline
- Start date
- 2022-08-03
- Primary completion
- 2025-06-27
- Completion
- 2026-08-01
- First posted
- 2022-08-04
- Last updated
- 2025-09-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05488366. Inclusion in this directory is not an endorsement.